Calcium folinate pentahydrate
Skin Toxicities
AmgenSmall moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Skin Toxicities cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Irinotecan Amgen | Phase 2 | B |
FLUOROURACILUM Amgen | Phase 2 | B |
PANITUMUMAB Amgen | Phase 2 | B |
Solu-Cortef Amgen | Phase 2 | B |
Same molecule, other indications
Calcium folinate pentahydrate is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →